# Sprint 3.3 — Medical Review / QC engineering verification

**Status: IMPLEMENTATION COMMITTED; CI pending at the time of report.**

## URS / FRS scope
URS-LIT-060–066, URS-LIT-106–110; FRS-LIT-012–016 and 021–022. Existing clinical services and shared specialist agents are not reimplemented here.

## Examined code
- `frontend/app/api/literature/review/medical/route.ts`: requires `MEDICAL_REVIEW` in Nexus Literature workspace before invoking `saveMedicalReview`.
- `frontend/lib/literature/review/review-workflow-service.ts`: tenant-filtered Medical Review worklist and recorded reviewer/status/version.
- `frontend/lib/literature/review/review-mutation-service.ts`: patient segmentation, Label/RSI and causality status prerequisites; database transaction, locked workspace, versioned Medical Review save, workflow transition, audit event.
- `frontend/lib/literature/intake-input/intake-input-governance.ts`: approved MR and completed review must precede Intake generation.
- `frontend/scripts/verify-cleanup-sprint4-literature.ts`: existing frontend CI verification script, now extended to detect missing finalized-MR locking, MR permission and Intake prerequisites.

## Confirmed defect / correction
**URS-LIT-064 / FRS-LIT-016** — `saveMedicalReview` had a locked workspace, but unlike patient/label/causality mutation functions, did not reject mutation after `REVIEW_COMPLETE`. A second Medical Review could overwrite the completed clinical disposition by updating the same review row.

**Fix:** added explicit `workspace.status === "REVIEW_COMPLETE"` rejection following the tenant-scoped row lock and before any MR update; commit `a1bb3152`. Added CI source regression checks in `verify-cleanup-sprint4-literature.ts`; commit `5b892f9f`. Controlled amendments remain separate, not created by this change.

## Verification / limitations
- Frontend CI run for `5b892f9f`: https://github.com/madhupadishala/Literature-Screening-Production/actions/runs/38061924061 (check live conclusion).
- The committed static assertions verify source contract presence, ordering and audit/permission dependencies. They do not simulate an actual clinical reviewer or database mutation.
- QC paths and specialist shared contracts should be separately assessed before marking the full Sprint 3.3 **CLOSED**. No new duplicate assessment agent should be built just to fulfill this sprint.
- Do not infer that passing frontend CI constitutes medical clinical validation.
